Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03533283
Title An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

follicular lymphoma

hematologic cancer

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Obinutuzumab + RO7082859

Obinutuzumab + Polatuzumab vedotin-piiq + RO7082859 + Tocilizumab

Atezolizumab + Obinutuzumab + RO7082859 + Tocilizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | BEL


No variant requirements are available.